Fast Facts: HIV and Hispanic/Latino People

At a glance

While HIV affects all people in the United States, Hispanic/Latino people are especially affected. Poverty, migration patterns, educational level, and language barriers may make it harder for some Hispanic/Latino people to seek and receive high-quality health care, including HIV testing, treatment, and other prevention and care services. Addressing these issues and other social and structural barriers can help improve health outcomes for Hispanic/Latino people.

A group of people huddled together, smiling.

Fast facts

HIV Incidence

HIV incidence refers to the estimated number of new HIV infections in a given year.

Of the 31,800 estimated new HIV infections in the US in 2022, 33% (10,500) were among Hispanic/Latino people. The overall Ending the HIV Epidemic in the US goal is to reduce new HIV infections to 9,300 by 2025 and 3,000 by 2030.

Estimated HIV infections among Hispanic/Latino people in the US, 2018-2022*

10,600 (2018) 10,200 (2019) 10,000 (2020) 9,800 (2021) 10,500 (2022)

Of the 31,800 estimated new HIV infections in the US in 2022, 33% (10,500) were among Hispanic/Latino people.

*Among people aged 13 and older.

Source: CDC. Estimated HIV incidence and prevalence in the United States, 2018–2022. HIV Surveillance Supplemental Report, 2024; 29(1).

Ending the HIV Epidemic Overall Goal: Decrease the estimated number of new HIV infections to 9,300 by 2025 and 3,000 by 2030.

HIV Diagnoses

HIV diagnoses refers to the number of people who received an HIV diagnosis during a given year.

In 2022, 32% of the 37,981 new HIV diagnoses in the US and associated territories and states were among Hispanic/Latino people. The overall Ending the HIV Epidemic goal is to reduce new diagnoses to 9,588 by 2025 and 3,000 by 2030.

HIV diagnoses among Hispanic/Latino people in the US and 6 territories and freely associated states, 2022

Hispanic/Latino people accounted for 32% (12,167) of the 37,981 people who received an HIV diagnosis in the US and 6 territories and freely associated states in 2022.*

*Among people aged 13 and older.

Source: CDC. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2024;35. The six territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands.

Ending the HIV Epidemic Overall Goal: Decrease the number of new HIV diagnoses to 9,588 by 2025 and 3,000 by 2030.

The image provides statistics on HIV diagnoses among Hispanic/Latino people in the US and associated territories in 2022. It shows that most new diagnoses were among men, with 87% of those attributed to male-to-male sexual contact. For women, 87% of diagnoses were due to heterosexual contact.

HIV diagnoses among Hispanic/Latino people in the US and 6 territories and freely associated states by sex and transmission category, 2022*†

Among Hispanic/Latino people, most new HIV diagnoses were among men.

Men (N=10,725)

  • Male-to-male sexual contact: 87% (9,374)
  • Heterosexual contact: 6% (630)
  • Injection Drug Use: 3% (359)
  • Male-to-male sexual contact and injection drug use: 3% (356)
  • Other‡: <1% (6)

Women (N=1,442)

  • Heterosexual Contact: 87% (1,261)
  • Injection Drug Use: 12% (174)
  • Other‡: <1% (7)

*Among people aged 13 and older. †Based on sex assigned at birth and includes transgender people. ‡Includes perinatal exposure, blood transfusion, hemophilia, and risk factors not reported or not identified.

Source: CDC. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2024:35. The six territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands.

From 2018 to 2022, HIV diagnoses increased 17% among Hispanic/Latino people overall. Although HIV diagnoses remained stable among young Hispanic/Latino people aged 13 to 24, those aged 45 to 54, and those aged 65 and older, more work is needed to reduce HIV diagnoses among all age groups.

The image presents data on trends in HIV diagnoses among Hispanic/Latino people in the US, its territories, and freely associated states from 2018 to 2022. The information is divided by sex and age groups. There were increases in HIV diagnoses among men (18%) and women (14%). Among age groups, people 25 to 34 and people 35 to 44 showed increases of 25% and 33%, respectively. People 55 to 64 also saw an 18% increase, while other age groups remained stable.

Trends in HIV diagnoses among Hispanic/Latino people in the US and 6 territories and freely associated states by sex and age, 2018-2022

Trends by Sex* 2018 (circle), 2022 (triangle)

  • Men: 18% increase
  • Women: 14% increase

Trends by Age† 2018 (circle), 2022 (triangle)

  • 13 to 24: Stable
  • 25 to 34: 25% increase
  • 35 to 44: 33% increase
  • 45 to 54: Stable
  • 55 to 64: 18% increase
  • 65 and older: Stable

Based on sex assigned at birth and includes transgender people.

† Does not include perinatal and other transmission categories.

Source: CDC. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2024;35. The six territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands.

Knowledge of Status

Knowledge of status refers to the estimated percentage of people with HIV who have received an HIV diagnosis.

The image provides data on knowledge of HIV status in the US for 2022 among Hispanic/Latino people. Out of 1.2 million people with HIV, 316,900 were Hispanic/Latino. While 87% of the general population with HIV knew their status, only 84% of Hispanic/Latino people with HIV did. The overall Ending the HIV Epidemic goal is to increase knowledge of status to 95% by 2025 and maintain it by 2030.

Knowledge of HIV status among Hispanic/Latino people in the US, 2022*

In 2022, an estimated 1.2 million people had HIV. Of those, 316,900 were Hispanic/Latino people.

For every 100 people with HIV, 87 knew their HIV status. For every 100 Hispanic/Latino people with HIV, 84 knew their HIV status.

Overall Ending the HIV Epidemic Goal: Increase the estimated percentage of people with HIV who have received an HIV diagnosis to at least 95% by 2025 and remain at 95% by 2030.

*Among people aged 13 and older. Source: CDC. Estimated HIV incidence and prevalence in the United States, 2018–2022. HIV Surveillance Supplemental Report, 2024; 29(1).

Viral suppression and barriers to care

Viral suppression refers to the percentage of people with diagnosed HIV who have less than 200 copies of HIV per milliliter of blood.

The infographic highlights the HIV care continuum for Hispanic/Latino people with diagnosed HIV in the U.S. in 2022. For every 100 Hispanic/Latino people with diagnosed HIV, 73 received some care, 55 were retained in care, and 64 achieved viral suppression. In the overall population, 76 received care, 54 were retained in care, and 65 were virally suppressed. The Ending the HIV Epidemic goal is to increase viral suppression to 95% by 2025 and maintain it through 2030.

HIV care continuum among Hispanic/Latino people with diagnosed HIV in 48 states and the District of Columbia, 2022*

Compared to all people with diagnosed HIV, Hispanic/Latino people have lower viral suppression rates. For every 100 Hispanic/Latino people with diagnosed HIV:

  • 73 received some HIV care †
  • 55 were retained in care ‡
  • 64 were virally suppressed **

For comparison, for every 100 people overall with diagnosed HIV, 76 received some care, 54 were retained in care, and 65 were virally suppressed.

*Among people aged 13 and older. † At least 1 viral load or CD4 test. ‡ Had 2 viral load or CD4 tests at least 3 months apart in a year. ** Based on most recent viral load test.

Source: CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022. HIV Surveillance Supplemental Report 2024;29(2). The six territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands.

Overall Ending the HIV Epidemic Goal: Increase the percentage of people with diagnosed HIV who are virally suppressed to at least 95% by 2025 and remain at 95% by 2030.

Many people with HIV experience challenges with achieving and maintaining viral suppression over time. Some of these challenges include missing HIV medical appointments, needing but not receiving other important health care services, or missing doses of HIV treatment.

The image presents data on HIV stigma among Hispanic/Latino people with diagnosed HIV in the US in 2022. The stigma score for this group is 29, compared to 30 for all people with HIV. The scoring system ranges from 0 (no stigma) to 100 (high stigma), measuring personalized stigma, disclosure concerns, self-image, and public attitudes. The goal is to achieve a score of 0, indicating no HIV stigma.

Median HIV stigma score among Hispanic/Latino people with diagnosed HIV in the US, 2022*

Hispanic/Latino people with HIV experience HIV stigma.

HIGH HIV STIGMA 100 29 Hispanic/Latino people with HIV 30 All people with HIV

GOAL 0 NO HIV STIGMA

Median HIV stigma scores are presented based on a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people with HIV.

*Among people aged 18 and older.

Source: CDC: Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States 2022 cycle (June 2022–May 2023). HIV Surveillance Special Report 2024;36.

The image presents data on self-rated health among Hispanic/Latino people diagnosed with HIV in the US in 2022. It highlights that 70% of all people with HIV and 69% of Hispanic/Latino people with HIV rated their overall health as good or better. People who rate their overall health as good or better may experience better outcomes related to HIV, such as treatment adherence and viral suppression.

Self-rated health among Hispanic/Latino people with diagnosed HIV in the US, 2022*

People who rate their overall health as good or better may experience better HIV-related outcomes, like adherence to treatment and viral suppression.

70% of all people with HIV rated their overall health as good or better†

69% of Hispanic/Latino people with HIV rated their overall health as good or better†

*Among people aged 18 and older. †Good or better self-rated health is defined as rating one's health as good, very good, or excellent (as opposed to poor or fair) at the time of interview. Source: CDC. Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States 2022 cycle (June 2022–May 2023). HIV Surveillance Special Report 2024:36.

The image provides data on the unmet mental health service needs of people with HIV in 2022, highlighting that 27% of all people with HIV and 23% of Hispanic/Latino people with HIV reported not receiving needed mental health services. Good mental health can make it easier for people with HIV to get and stay in HIV care.

Percentage of Hispanic/Latino people with HIV who reported an unmet need for mental health services, 2022*†

Good mental health can make it easier for people with HIV to get and stay in HIV care.

27% of all people with HIV reported needing, but not receiving mental health services in the past 12 months

23% of Hispanic/Latino people with HIV reported needing, but not receiving mental health services in the past 12 months

*Among people aged 18 and older.

† Needing, but not receiving, services from a mental health professional among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months. Source: CDC. Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States 2022 cycle (June 2022–May 2023). HIV Surveillance Special Report 2024,36.

The image presents data from 2022 on hunger or food insecurity, unemployment, and unstable housing or homelessness among Hispanic/Latino people diagnosed with HIV in the US, which can make it difficult for people with HIV to access HIV-related care and maintain viral suppression. Hispanic/Latino people with HIV reported higher rates of unstable housing or homelessness (23%) compared to the overall population with HIV (19%).

Hunger or food insecurity, unemployment, and unstable housing or homelessness among Hispanic/Latino people with diagnosed HIV in the US, 2022*

Hunger or food insecurity, unemployment, and unstable housing or homelessness can make it difficult for people with HIV to access HIV-related care and maintain viral suppression.

Percentage of people with HIV who reported food insecurity, unemployment, or unstable housing in the past 12 months:

Hispanic/Latino people with HIV:

  • 12% Hunger or food insecurity†
  • 18% Unemployment‡
  • 23% Unstable housing or homelessness**

All people with HIV:

  • 11% Hunger or food insecurity†
  • 18% Unemployment‡
  • 19% Unstable housing or homelessness**

*Among people aged 18 and older. †Going without food due to lack of money during the past 12 months. ‡Those who reported being unemployed at the time of the interview, excluding persons who were unable to work. **Experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted at any time) or homelessness (living on the street, in a shelter, in a single-room-occupancy hotel, or in a car at any time) during the past 12 months.

Source: CDC. Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States 2022 cycle (June 2022–May 2023), HIV Surveillance Special Report 2024;36.

What CDC is doing

CDC works every day to maximize the effectiveness of current HIV prevention interventions and strategies. CDC provides research and guidance on effective interventions to reach people in diverse communities, capacity building assistance for those working in HIV prevention and care services, and many other core components of public health, including data collection and reporting, community and partner engagement, and social marketing campaigns to reach people affected by HIV.

Funding state, territorial, and local health departments is CDC's largest investment in HIV prevention for Hispanic/Latino people. Some key indicators are as follows:

The image presents data on the percentage of CDC-funded HIV tests conducted among Hispanic/Latino persons in the U.S. from 2019 to 2022. The percentage increased from 23.6% in 2019 to 27.7% in 2022, with a total of 533,364 tests conducted in 2022.

HIV tests among Hispanic or Latino* persons, United States, 2019-2022

Of the estimated 1,928,806 CDC-funded HIV tests conducted in 2022, 533,364 (27.7%) were among Hispanic or Latino* persons.

2019 (N=591,831) - 23.6% 2020 (N=310,699) - 23.1% 2021 (N=453,729) - 25.9% 2022 (N=533,364) - 27.7%

*Hispanic or Latino persons can be of any race. Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The chart presents data on HIV testing among Hispanic/Latino people in the United States for 2022, categorized by age group. The highest percentage of tests was conducted in the 20 to 29 age group (33.6%), followed by the 30 to 39 age group (27.4%). Individuals aged 50 and over accounted for 16.7% of the tests, and those aged 40 to 49 accounted for 16.5%. The 13 to 19 age group represented 5.2% of the tests, while less than 1% of tests were conducted on individuals under 13.

HIV tests among Hispanic or Latino* persons by age, United States, 2022

<13 (N=1,039) - <1% 13 to 19 (N=27,940) - 5.2% 20 to 29 (N=179,359) - 33.6% 30 to 39 (N=146,012) - 27.4% 40 to 49 (N=88,167) - 16.5% ≥50 (N=88,929) - 16.7%

*Hispanic or Latino persons can be of any race. Note: Data with missing values were excluded from the analysis. Therefore, the totals may not sum up to 100%. Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The chart presents data on HIV testing among Hispanic/Latino people in non-health care settings in the United States for 2022. The testing percentages are shown for different groups: MSM (men who have sex with men) at 35.3%, MSM who inject drugs at 1.2%, persons who inject drugs at 4.8%, heterosexual men at 20.8%, and heterosexual women at 24.2%.

HIV tests among Hispanic or Latino* persons in non-health care settings† by population group,‡ United States, 2022

MSM (N=39,509): 35.3%

MSM who inject drugs (N=1,291): 1.2%

Persons who inject drugs (N=5,317): 4.8%

Heterosexual Men (N=23,266): 20.8%

Heterosexual Women (N=27,075): 24.2%

*Hispanic or Latino persons can be of any race. †Non-health care settings may include schools/educational facilities, churches, and bars. ‡Population group is based on sexual and injection drug use behaviors of persons during the last five years prior to the HIV test. The collection of these data is required for all tests conducted in non-health care settings and for persons who were HIV positive in health care settings. MSM includes men who reported male-to-male sexual contact in the past five years. Persons who inject drugs includes persons who reported injection drug use in the past five years. MSM who inject drugs includes men who reported both male-to-male sexual contact and injection drug use in the past five years.

Note: Data with missing values were excluded from the analysis. Therefore, the totals may not sum up to 100%.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb© (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The image presents data on HIV testing among Hispanic/Latino people across different U.S. Census regions in 2022. The South had the highest percentage of tests at 54.9%, followed by the West at 22.7%, the Northeast at 14.7%, the Midwest at 5.4%, and Puerto Rico & the U.S. Virgin Islands at 2.3%.

HIV tests among Hispanic or Latino* persons by U.S. Census Region, United States, 2022

West 22.7% N=121,309

Midwest 5.4% N=28,601

Northeast 14.7% N=78,196

South 54.9% N=293,026

PR & USVI 2.3% N=12,232

*Hispanic or Latino persons can be of any race. Abbreviations: PR, Puerto Rico; USVI, U.S. Virgin Islands. Note: The five U.S. Census Regions represented in this graph include the following: West, Midwest, Northeast, South, and Puerto Rico and the U.S. Virgin Islands. Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

In 2022, among Hispanic or Latino persons in the United States, 84 out of every 100 newly diagnosed with HIV were linked to medical care within 30 days, and 44 out of every 100 eligible individuals received a referral to a PrEP provider.

Linkage to HIV medical care* and PrEP referral† among Hispanic or Latino‡ persons, United States, 2022

For every 100 Hispanic or Latino persons newly diagnosed with HIV 84 were linked to HIV medical care within 30 days after diagnosis

For every 100 Hispanic or Latino persons eligible for a PrEP referral 44 were referred to a PrEP provider

*Persons newly diagnosed with HIV are considered linked to HIV medical care if they attended an appointment for HIV medical care within 30 days after diagnosis. For linkage to care, HIV medical care includes medical services for HIV, including evaluating immune system function and screening treatment, and prevention of opportunistic infections.

† Referral to a PrEP provider is defined as a process involving the provision of information on who the providers are, what documents referred person should take with them, how to get to the provider's agency, and what to expect from the referral process.

‡ Hispanic or Latino persons can be of any race.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The chart presents data on the linkage to HIV medical care within 30 days of diagnosis for Hispanic or Latino persons newly diagnosed with HIV in the United States in 2022. The data is segmented by age group. The highest percentage is in the 13 to 19 age group (93.8%), while the lowest is in the 40 to 49 age group (80.8%).

Linkage to HIV medical care within 30 days after diagnosis* among Hispanic or Latino† persons newly diagnosed with HIV by age, United States, 2022

NA‡

93.8%

84.0%

86.0%

80.8%

82.0%

Age (Years):

<13

13 to 19 (45/48)

20 to 29 (901/1,073)

30 to 39 (936/1,089)

40 to 49 (328/406)

≥50 (187/228)

*Persons newly diagnosed with HIV are considered linked to HIV medical care if they attended an appointment for HIV medical care within 30 days after diagnosis. For linkage to care, HIV medical care includes medical services for HIV, including evaluating immune system function and screening treatment, and prevention of opportunistic infections. † Hispanic or Latino persons can be of any race. ‡ Indicates no linkage data available for age <13 years.

Note: Data with missing values were excluded from the analysis.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The image presents data on the linkage to HIV medical care within 30 days after diagnosis among Hispanic or Latino individuals newly diagnosed with HIV in the United States in 2022. The data is categorized by population groups: MSM (Men who have sex with men) had the highest linkage rate at 87.2%. MSM who inject drugs had an 81.4% linkage rate. Persons who inject drugs had the lowest linkage rate at 69.1%. Heterosexual men had a linkage rate of 77.0%. Heterosexual women had a linkage rate of 74.8%.

Linkage to HIV medical care within 30 days after diagnosis* among Hispanic or Latino† persons newly diagnosed with HIV by population group,‡ United States, 2022

87.2% MSM (1,785/2,048)

81.4% MSM who inject drugs (70/86)

69.1% Persons who inject drugs (38/55)

77.0% Heterosexual Men (154/200)

74.8% Heterosexual Women (101/135)

*Persons newly diagnosed with HIV are considered linked to HIV medical care if they attended an appointment for HIV medical care within 30 days after diagnosis. For linkage to care, HIV medical care includes medical services for HIV, including evaluating immune system function and screening treatment, and prevention of opportunistic infections. † Hispanic or Latino persons can be of any race. ‡ Population group is based on sexual and injection drug use behaviors of persons during the last five years prior to the HIV test. The collection of these data is required for all tests conducted in non-health care settings and for persons who were HIV positive in health care settings. MSM includes men who reported male-to-male sexual contact in the past five years. Persons who inject drugs includes persons who reported injection drug use in the past five years. MSM who inject drugs includes men who reported both male-to-male sexual contact and injection drug use in the past five years. Note: Data with missing values were excluded from the analysis. Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The image presents data from 2022 on linkage to HIV medical care within 30 days of diagnosis among Hispanic or Latino individuals across different U.S. Census regions. The percentage of linkage to care is highest in the Northeast (89.4%), followed by the South (88.4%), Puerto Rico & U.S. Virgin Islands (87.3%), Midwest (76.4%), and West (73.0%).

Linkage to HIV medical care within 30 days after diagnosis* among Hispanic or Latino† persons newly diagnosed with HIV by U.S. Census Region, United States, 2022

West 73.0% 500/685

Midwest 76.4% 84/110

Northeast 89.4% 339/379

South 88.4% 1,366/1,546

PR & USVI 87.3% 110/126

*Persons newly diagnosed with HIV are considered linked to HIV medical care if they attended an appointment for HIV medical care within 30 days after diagnosis. For linkage to care, HIV medical care includes medical services for HIV, including evaluating immune system function and screening treatment, and prevention of opportunistic infections.

† Hispanic or Latino persons can be of any race.

Abbreviations: PR, Puerto Rico; USVI, U.S. Virgin Islands

Note 1: The five U.S. Census Regions represented in this graph include the following: West, Midwest, Northeast, South, and Puerto Rico and the U.S. Virgin Islands.

Note 2: Data with missing values were excluded from the analysis.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The chart provides data on the referral rates to PrEP providers among Hispanic or Latino people eligible for referral in the United States in 2022, segmented by age groups. The highest referral rate is among the 30 to 39 age group at 46.9%, while the lowest is in the under 13 age group at 29.6%. The data is sourced from CDC-funded HIV testing services across multiple jurisdictions.

Referral to a PrEP provider* among Hispanic or Latino† persons who were eligible for a PrEP referral by age, United States, 2022

<13 (34/115) 29.6%

13 to 19 (2,216/6,378) 34.7%

20 to 29 (24,718/55,684) 44.4%

30 to 39 (19,598/41,778) 46.9%

40 to 49 (8,541/19,680) 43.4%

≥50 (5,988/14,787) 40.5%

*Referral to a PrEP provider is defined as a process involving the provision of information on who the providers are, what documents referred person should take with them, how to get to the provider's agency, and what to expect from the referral process.

†Hispanic or Latino persons can be of any race.

Note: Data with missing values were excluded from the analysis.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The chart illustrates the percentage of Hispanic or Latino people referred to a PrEP provider in non-health care settings across different population groups in the U.S. during 2022. The groups include MSM (men who have sex with men), MSM who inject drugs, persons who inject drugs, heterosexual men, and heterosexual women. MSM who inject drugs had the highest referral rate at 63.2%, while heterosexual men had the lowest at 37.8%.

Referral to a PrEP provider* among Hispanic or Latino† persons who were eligible for a PrEP referral in non-health care settings‡ by population group,§ United States, 2022

MSM (17,298/28,624) 60.4%

MSM who inject drugs (593/938) 63.2%

Persons who inject drugs (1,929/3,552) 54.3%

Heterosexual Men (4,202/11,109) 37.8%

Heterosexual Women (4,901/12,705) 38.6%

*Referral to a PrEP provider is defined as a process involving the provision of information on who the providers are, what documents referred person should take with them, how to get to the provider's agency, and what to expect from the referral process. † Hispanic or Latino persons can be of any race. ‡ Non-health care settings may include schools/educational facilities, churches, and bars. § Population group is based on sexual and injection drug use behaviors of persons during the last five years prior to the HIV test. The collection of these data is required for all tests conducted in non-health care settings and for persons who were HIV positive in health care settings. MSM includes men who reported male-to-male sexual contact in the past five years. Persons who inject drugs includes persons who reported injection drug use in the past five years. MSM who inject drugs includes men who reported both male-to-male sexual contact and injection drug use in the past five years.

Note: Data with missing values were excluded from the analysis.

Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.

The image presents data on referrals to PrEP providers among Hispanic or Latino persons eligible for PrEP referrals in different U.S. Census regions in 2022. The South had the highest referral rate at 53.4%, while the Northeast had the lowest at 24.3%. The West and PR & USVI had similar rates, around 39.9% and 39.4%, respectively. The Midwest had a referral rate of 50.7%.

Referral to a PrEP provider* among Hispanic or Latino† persons who were eligible for a PrEP referral by U.S. Census Region, United States, 2022

West: 39.9% (12,364/30,971) Midwest: 50.7% (3,904/7,704) Northeast: 24.3% (6,730/27,732) South: 53.4% (37,189/69,627) PR & USVI: 39.4% (1,088/2,759)

*Referral to a PrEP provider is defined as a process involving the provision of information on who the providers are, what documents referred person should take with them, how to get to the provider's agency, and what to expect from the referral process. † Hispanic or Latino persons can be of any race. Abbreviations: PR, Puerto Rico; USVI, U.S. Virgin Islands Note 1: The five U.S. Census Regions represented in this graph include the following: West, Midwest, Northeast, South, and Puerto Rico and the U.S. Virgin Islands. Note 2: Data with missing values were excluded from the analysis. Source: National HIV Prevention Program Monitoring and Evaluation data from EvaluationWeb® (January 1, 2022 – December 31, 2022). This data describes CDC-funded HIV tests and testing services outcomes in 60 jurisdictions and 119 community-based organizations directly funded by the CDC in the United States, Puerto Rico, and the U.S. Virgin Islands.